We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Stem Cell Differentiation Depends on the Central Metabolic Regulator AMPK

By LabMedica International staff writers
Posted on 11 May 2016
The ability of stem cells to differentiate into mature tissue depends on the activity of the central metabolic regulator AMP-activated protein kinase (AMPK).

Investigators at the Salk Institute for Biological Studies (La Jolla, CA, USA) reported in the March 2016 issue of the journal Genes & Development that although AMPK-deficient embryonic stem cells (ESCs) were normal in the pluripotent state, these cells displayed profound defects upon differentiation, failing to generate chimeric embryos and preferentially adopting an ectodermal fate at the expense of the endoderm during embryoid body (EB) formation.

EBs lacking AMPK exhibited reduced levels of Tfeb (Transcription factor EB), a master transcriptional regulator of lysosomes, which led to diminished endolysosomal function. More...
Reintroduction of Tfeb into the dysfunctional cells restored normal development and differentiation.

"Even though there is great interest in AMPK related to diabetes and cancer, frankly nothing was known about how this fuel gauge process changes in different cell populations during development," said senior author Dr. Reuben Shaw, professor of molecular and cell biology at the Salk Institute for Biological Studies. "It was thought that lysosomes and AMPK were connected somehow, but no one had dreamed that you would get no lysosomes if you do not have this fuel gauge. Connecting the AMPK pathway to lysosomes begs the question of whether this pathway is part of anticancer pathways as well. We are decoding some of these underlying connections that might indicate when and how a cancer drugs might be useful. This work may also help up make better, more specific ways of targeting lysosomes in cancer."

Related Links:
Salk Institute for Biological Studies


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.